This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saw, J. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Saw, J. Articles by Topol, E. J.

The Influence of Peripheral Arterial Disease on Outcomes

A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials

Jacqueline Saw, MD, FRCPC^_*, Deepak L. Bhatt, MD, FACC^,_*, David J. Moliterno, MD, FACC, Sorin J. Brener, MD, FACC, Steven R. Steinhubl, MD, FACC, A. Michael Lincoff, MD, FACC, James E. Tcheng, MD, FACC, Robert A. Harrington, MD, FACC, Maarten Simoons, MD, FACC^||, TingFei Hu, MS, Mobeen A. Sheikh, MD, Dean J. Kereiakes, MD, FACC^¶ and Eric J. Topol, MD, FACC

^_* Department of Medicine, Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Department of Cardiovascular Medicine, the Cleveland Clinic Foundation, Cleveland, Ohio
Department of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky
Division of Cardiology, Duke University Medical Center, Durham, North Carolina
^|| Department of Cardiology, Erasmus University, Rotterdam, the Netherlands
^¶ Lindner Center and the Ohio Heart and Vascular Center at the Christ Hospital, Cincinnati, Ohio

View larger version (10K): [in a new window]   Figure 1 Unadjusted analysis comparing 7-day, 30-day, 6-month, and 1-year mortality among patients with peripheral arterial disease (PAD) versus no PAD.

View larger version (23K): [in a new window]   Figure 2 The 1-year Kaplan-Meier unadjusted mortality curve. PAD = peripheral arterial disease.

View larger version (33K): [in a new window]   Figure 3 Multivariable analyses evaluating adjusted hazard ratio (HR) mortality outcomes for individual studies and pooled data at (A) 30 days, (B) 6 months, and (C) 1 year. CI = confidence interval; PAD = peripheral arterial disease.

View larger version (31K): [in a new window]   Figure 4 Subanalysis of 6 randomized percutaneous coronary intervention trials comparing glycoprotein (GP) IIb/IIIa inhibitor versus placebo, stratifying composite event rates (death, myocardial infarction, or target vessel revascularization) according to peripheral arterial disease (PAD) presence. RRR = relative risk reduction.